AR089771A1 - Derivados de bencil sulfonamida utiles como inhibidores de mogat-2 - Google Patents

Derivados de bencil sulfonamida utiles como inhibidores de mogat-2

Info

Publication number
AR089771A1
AR089771A1 ARP130100180A ARP130100180A AR089771A1 AR 089771 A1 AR089771 A1 AR 089771A1 AR P130100180 A ARP130100180 A AR P130100180A AR P130100180 A ARP130100180 A AR P130100180A AR 089771 A1 AR089771 A1 AR 089771A1
Authority
AR
Argentina
Prior art keywords
mogat
bencil
inhibitors
derivatives
useful
Prior art date
Application number
ARP130100180A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47148691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089771(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR089771A1 publication Critical patent/AR089771A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP130100180A 2012-01-31 2013-01-21 Derivados de bencil sulfonamida utiles como inhibidores de mogat-2 AR089771A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261592717P 2012-01-31 2012-01-31
EP12382432 2012-11-06

Publications (1)

Publication Number Publication Date
AR089771A1 true AR089771A1 (es) 2014-09-17

Family

ID=47148691

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100180A AR089771A1 (es) 2012-01-31 2013-01-21 Derivados de bencil sulfonamida utiles como inhibidores de mogat-2

Country Status (27)

Country Link
US (1) US8575352B2 (OSRAM)
EP (1) EP2809651B1 (OSRAM)
JP (1) JP2015511232A (OSRAM)
KR (1) KR20140106750A (OSRAM)
CN (1) CN104066719B (OSRAM)
AP (1) AP2014007794A0 (OSRAM)
AR (1) AR089771A1 (OSRAM)
AU (1) AU2013215468A1 (OSRAM)
BR (1) BR112014018636A8 (OSRAM)
CA (1) CA2859995A1 (OSRAM)
CL (1) CL2014001861A1 (OSRAM)
CO (1) CO7010839A2 (OSRAM)
CR (1) CR20140322A (OSRAM)
DO (1) DOP2014000178A (OSRAM)
EA (1) EA201491276A1 (OSRAM)
ES (1) ES2590929T3 (OSRAM)
GT (1) GT201400167A (OSRAM)
HK (1) HK1199025A1 (OSRAM)
IL (1) IL233712A0 (OSRAM)
MA (1) MA35886B1 (OSRAM)
MX (1) MX2014008599A (OSRAM)
PE (1) PE20141679A1 (OSRAM)
PH (1) PH12014501711A1 (OSRAM)
SG (1) SG11201404106QA (OSRAM)
TW (1) TW201343629A (OSRAM)
WO (1) WO2013116075A1 (OSRAM)
ZA (1) ZA201404836B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112323A1 (en) 2012-01-23 2013-08-01 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors
US8993568B2 (en) 2012-01-31 2015-03-31 Eli Lilly And Company Morpholinyl derivatives useful as MOGAT-2 inhibitors
CN104768941B (zh) 2012-11-06 2016-08-24 伊莱利利公司 用作MoGAT-2抑制剂的新苄基磺酰胺化合物
MX389242B (es) 2015-06-15 2025-03-20 Nmd Pharma As Compuestos para su uso en el tratamiento de trastornos neuromusculares
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有mgat2抑制活性的縮合環衍生物
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US12440477B2 (en) 2017-12-14 2025-10-14 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US10385028B2 (en) 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
WO2020145369A1 (ja) 2019-01-11 2020-07-16 塩野義製薬株式会社 Mgat2阻害活性を有するジヒドロピラゾロピラジノン誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1655283A1 (en) * 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
CN101087771A (zh) * 2004-11-10 2007-12-12 辉瑞大药厂 经取代n-磺酰基氨基苄基-2-苯氧基乙酰胺化合物
EP1824837B1 (en) * 2004-11-10 2008-08-13 Pfizer, Inc. Substituted n-sulfonylaminobenzyl-2-phenoxy acetamide compounds
CA2662766C (en) * 2006-09-08 2011-08-09 Pfizer Products Inc. Diaryl ether derivatives and uses thereof
EP2078719A4 (en) * 2006-09-28 2009-11-11 Dainippon Sumitomo Pharma Co COMPOUND WITH BICYCLIC PYRIMIDINE STRUCTURE AND THE COMPOUND CONTAINING PHARMACEUTICAL COMPOSITION
CA2669311C (en) * 2006-11-13 2011-09-20 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
AU2010216633A1 (en) 2009-02-23 2011-09-08 Msd K.K. Pyrimidin-4(3H)-one derivatives
WO2013112323A1 (en) 2012-01-23 2013-08-01 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors
US8993568B2 (en) 2012-01-31 2015-03-31 Eli Lilly And Company Morpholinyl derivatives useful as MOGAT-2 inhibitors

Also Published As

Publication number Publication date
EP2809651B1 (en) 2016-06-29
CO7010839A2 (es) 2014-07-31
MX2014008599A (es) 2014-08-22
AU2013215468A1 (en) 2014-07-10
TW201343629A (zh) 2013-11-01
CN104066719B (zh) 2016-08-24
EP2809651A1 (en) 2014-12-10
CN104066719A (zh) 2014-09-24
JP2015511232A (ja) 2015-04-16
CA2859995A1 (en) 2013-08-08
KR20140106750A (ko) 2014-09-03
PE20141679A1 (es) 2014-11-08
BR112014018636A8 (pt) 2017-07-11
SG11201404106QA (en) 2014-08-28
CL2014001861A1 (es) 2014-11-07
MA35886B1 (fr) 2014-12-01
EA201491276A1 (ru) 2014-10-30
US8575352B2 (en) 2013-11-05
GT201400167A (es) 2015-05-28
BR112014018636A2 (OSRAM) 2017-06-20
AP2014007794A0 (en) 2014-07-31
ZA201404836B (en) 2017-08-30
US20130197039A1 (en) 2013-08-01
ES2590929T3 (es) 2016-11-24
DOP2014000178A (es) 2014-08-31
PH12014501711A1 (en) 2014-10-13
WO2013116075A1 (en) 2013-08-08
HK1199025A1 (en) 2015-06-19
CR20140322A (es) 2014-08-25
IL233712A0 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
AR102977A1 (es) Inhibidores de erk
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
MX373196B (es) Inhibidores de histona desacetilasa novedosos.
AR093759A1 (es) Dihidropiridona p1 como inhibidores del factor xia
EA201591455A1 (ru) Производные бензимидазолона в качестве ингибиторов бромодомена
AR101558A1 (es) Difluoropirrolidinas como moduladores del receptor de orexina
CR20120417A (es) Inhibidores de virus flaviviridae
MX342212B (es) Inhibidores de neprilisina.
CR20150018A (es) Inhibidores macrocíclicos de virus flaviviridae
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
CU24385B1 (es) Compuestos éteres de arilo útiles para tratar cancer de célula renal
AR090474A1 (es) Compuestos de tetrahidropirrolotiazina
AR094959A1 (es) Compuestos de imidazo piridina
AR089550A1 (es) Compuestos quimicos
AR091431A1 (es) Compuestos de acido dimetil-benzoico
AR097866A1 (es) Derivados de 4-azaindol
AR107428A1 (es) COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC
AR091773A1 (es) Inhibidores de la histona desacetilasa y composiciones y sus metodos de uso
DOP2014000178A (es) Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2
CR20160030A (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
AR091770A1 (es) Indolcarbonitrilos moduladores selectivos de receptores androgenicos
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T

Legal Events

Date Code Title Description
FB Suspension of granting procedure